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The nonmevalonate route to isoprenoid biosynthesis is essential in Gram-negative bacteria and apicomplexan
parasites. The enzymes of this pathway are absent from mammals, contributing to their appeal as
chemotherapeutic targets. One enzyme, 2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase (IspF), has
been validated as a target by genetic approaches in bacteria. Virtual screening against Escherichia coli IspF
(EcIspF) was performed by combining a hierarchical ﬁltering methodology with molecular docking. Docked
compounds were inspected and 10 selected for experimental validation. A surface plasmon resonance assay
was developed and two weak ligands identiﬁed. Crystal structures of EcIspF complexes were determined to
support rational ligand development. Cytosine analogues and Zn2+-binding moieties were characterized.
One of the putative Zn2+-binding compounds gave the lowest measured KD to date (1.92 ( 0.18 µM).
These data provide a framework for the development of IspF inhibitors to generate lead compounds of
therapeutic potential against microbial pathogens.
Introduction
All isoprenoids are derived from two precursors, dimethylallyl
diphosphate and isopentenyl diphosphate. The biosynthesis of
these simple ﬁve-carbon compounds, which contribute to a
plethora of important metabolites and natural products, is an
important area of chemical biology. The precursors are either
synthesized via the classical mevalonate pathway (MVA
a)
1 or
the more recently discovered nonmevalonate pathway.
2-4 The
MVA pathway is present in animals, fungi, the cytoplasm of
phototrophic organisms, some eubacteria, and archaea,
4-6
whereas the nonmevalonate pathway is present in most eubac-
teria,
4 in the chloroplasts of phototrophic organisms such as
algae, liverworts, and higher plants,
6 and in cyanobacteria and
diatoms.
7 It is also found in unicellular eukaryotes with an
evolutionary linkage to photosynthetic phyla, such as Prototheca
wickerhamii
8 and Plasmodium sp.
4,9 On the basis of chemical
and genetic data, the enzymes of the nonmevalonate pathway
are deemed attractive chemotherapeutic targets.
4 They are absent
from humans and occur in many of the world’s most serious
pathogenic microorganisms, including Mycobacterium tuber-
culosis and Plasmodium falciparum, the causal agents for
tuberculosis and malaria, respectively.
9-12 There are seven
enzymes in the pathway, and gene knockouts indicate that all
are essential in bacteria.
4,10,12,13 Such genetic validation is
complemented by the chemical validation of 1-deoxyxylulose
5-phosphate (DOXP) reductoisomerase (IspC), the second
enzyme in the pathway, using the antimicrobial fosmidomycin.
11,14
The subject of this study is the ﬁfth enzyme in the pathway,
2C-methyl-D-erythritol-2,4-cyclodiphosphate (MECDP) syn-
thase, or IspF. This enzyme converts 4-diphosphocytidyl-2C-
methyl-D-erythritol-2-phosphate into MECDP and CMP (Figure
1).
15 Structural and biochemical studies of IspF from several
species have been reported.
16-25 IspF forms a homotrimer built
around a   prism with three active sites, each of which is formed
in a cleft between pairs of subunits.
16-18 The active site
comprises a rigid, nucleotide-Zn2+-binding pocket and a ﬂexible
loop to bind the 2C-methyl-D-erythritol-2-phosphate (ME2P)
fragment of the substrate. A second divalent cation (Mg2+ or
Mn2+), positioned between the R- and  -phosphates of the
substrate, acts in concert with the Zn2+ to align and polarize
the substrate for catalysis.
16,18 We have adopted a structure-
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Figure 1. The reaction catalyzed by IspF.
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Published on Web 03/25/2009based approach to identify inhibitors of IspF and screened, in
silico, a database of commercially available compounds against
the nucleotide-Zn2+-binding pocket. The structure of E. coli IspF
(EcIspF) bound to CDP
16 was used to identify features
considered important for ligand binding and afﬁnity. A hierar-
chical ﬁltering methodology and molecular docking with
FlexX
26 generated several hits, which were then veriﬁed with
X-ray crystallography and a surface plasmon resonance (SPR)
assay. In addition, a more focused set of compounds was used
to probe the cytidine and Zn2+-binding sites, yielding a ligand
with low micromolar binding afﬁnity.
Results and Discussion
Protein Structure Selection. The selection of the protein
structure to provide the template for ligand discovery is critical
because the performance of molecular docking depends on the
conformation of the active site residues of the target. Although
our ultimate interest is to discover inhibitors of P. falciparum
(PfIspF) and M. tuberculosis (MtIspF), these structures are not
known, and EcIspF was selected as the template for virtual
screening based on a number of criteria. The EcIspF enzyme is
the best characterized following detailed biochemical analyses
and with high resolution crystal structures available of the
enzyme bound to a number of ligands including the substrate
and product. There is high overall sequence homology between
the active sites of EcIspF, PfIspF, and MtIspF. The residues
that coordinate the two divalent cations are conserved, as are
the residues that interact directly with the substrate (Figure
2).
16,21 In addition, the established protocols for overexpression,
puriﬁcation, and crystallization of EcIspF facilitated experi-
mental validation of putative ligands.
We decided to concentrate efforts on the cytidine-binding
pocket. This section offers a relatively static part of the active
site in comparison to the ME2P-binding pocket. Twelve crystal
structures of EcIspF were available, and selection criteria were
applied to select one for virtual screening. Structures that did
not contain a ligand were eliminated and because the Zn2+-
binding site comprised part of the target, structures without this
cation were also discarded. The remaining choices were complex
structures of EcIspF bound to CMP, CDP, or product (CMP
and MECDP). EcIspF-CMP complexes were eliminated be-
cause CMP is a substructure of the CDP and product complexes.
In some instances, redundant complexes were present and the
highest resolution structure was selected. At the end of this
process, two structures of EcIspF remained: EcIspF-CDP
(Protein Data Bank (PDB) code 1GX1, at 1.8 Å resolution) and
EcIspF-CMP-MECDP (PDB 1H48, 2.3 Å resolution). The
EcIspF-CDP structure was chosen by virtue of the higher
resolution of the analysis.
Validation of FlexX with EcIspF for Virtual Screening.
It was ﬁrst necessary to assess the suitability of FlexX
26 for
our modeling, and it was used to generate binding modes of
CDP in the active site of EcIspF. FlexX can apply two scoring
functions, F-Score and DrugScore, to rank binding modes, and
both were evaluated. In addition, the quality of each binding
pose was assessed by the root mean squared deviation (rmsd)
of atomic positions between the calculated and experimentally
determined binding modes. The ligand poses that are generated
are deﬁned as “well-docked” if they display an rmsd of less
than 2.0 Å from the experimental structure.
27 When CDP was
docked back into the active site of 1GX1, only 70% of the top
20 poses ranked by F-Score had rmsd values signiﬁcantly less
than this threshold value compared to 100% by DrugScore. The
closest generated pose, which was ranked ninth by DrugScore,
was within 0.6 Å of the experimental conformation (data not
shown). These results demonstrate the suitability of FlexX/
DrugScore and the applied docking protocol for this enzyme.
Hierarchical Filtering and Virtual Screening. We adopted
a three-step hierarchical ﬁltering approach, removing compounds
based on molecular complexity, topology, and functionality.
28,29
Initially, ﬁlters were applied to a database of approximately 1
million commercially available compounds so that only those
with less than seven rotatable bonds and a molecular mass below
450 Da were retained. These criteria are based on theoretical
30
and empirical
31 arguments, suggesting that lead compounds
should be of limited complexity to allow for subsequent lead
optimization. In the second step, a three-dimensional pharma-
cophore hypothesis was constructed based on the interactions
formed between CDP and EcIspF.
16 This pharmacophore
hypothesis (Figure 3) was composed of a hydrophobic compo-
nent (H), centered on the pyrimidine of CDP, a hydrogen bond
donor group (D1) based on the exocyclic amine group, and two
hydrogen bond acceptor groups derived from N3 (A2) and O2
(A3) of cytosine (Figure 3). The hydrogen bond partners on
EcIspF that complement the pharmacophore are the hydroxyl
group of Thr133 (A1) and the main chain amides of Met103
(D2) and Leu106 (D3), respectively (Figure 3). The pharma-
cophore ﬁltering procedure selected 4063 compounds, which
were docked into the EcIspF active site. Spatial constraints of
1.0 Å for the hydrophobic feature and 0.7 Å for donor and
Figure 2. Sequence alignment of IspF from E. coli, M. tuberculosis, and the catalytic domain of the P. falciparum protein. The secondary structure
of EcIspf is depicted as purple arrows for  -strands, yellow cylinders for R-helices, red cylinders for 310-helices. Residues whose identity is strictly
conserved in all three sequences are boxed in black, conservative substitutions in gray. Grey triangles mark three residues that coordinate Zn2+, and
an open triangle the Mg2+/Mn 2+-binding Glu-135. Circles mark CDP-binding residues (open and ﬁlled to distinguish subunits). The highly conserved
segment leading into a1 forms the ME2P binding site.
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of chemical interactions of potential ligands with those observed
in the EcIspF-CDP complex. The top 250 hits were inspected
visually, and 10 compounds selected for experimental validation
(Table 1) based on a number of criteria. It was judged important
that there was a complementarity of the ligand and protein
surfaces, reasonable internal geometry of the ligand in the
binding pose, proximity of the hydrophobic center of the ligand
to the cytosine binding pocket, and that reasonable hydrogen
bonding interactions, typically with the separation of donor and
acceptor groups in the range 2.4-3.5 Å, were predicted.
Binding Afﬁnities of Compounds to EcIspF. An SPR assay
with immobilized EcIspF was developed (Figure 4) in order to
determine the binding afﬁnities of the selected compounds
(Table 1). Five of these compounds required signiﬁcant
concentrations of dimethyl sulfoxide (DMSO) in order to
dissolve, compromising the use of SPR. Consequently, binding
for ﬁve of the compounds was analyzed. A series of concentra-
tions of each compound ranging from 0.1 µM to 10 mM were
applied for the assay. The binding responses were recorded as
a function of time and, at all compound concentrations, the
responses reached equilibrium and dissociated rapidly, indicating
that binding was reversible. Only compounds 6 and 7 yielded
quantiﬁable data. Values for KD were obtained by ﬁtting the
steady-state binding curves to a 1:1 Langmuir binding model.
Compounds 6 and 7 are weak ligands, having KD values of 20.5
( 2.23 and 0.925 ( 0.71 mM, respectively. The binding
afﬁnities of CMP (0.903 ( 0.107 mM) and CDP (0.097 ( 0.006
mM) were also determined, for the ﬁrst time, for reference.
CDP binds EcIspF at least 10-fold more tightly than CMP,
6,o r7. Compounds 6 and 7 are both CMP analogues and, like
CMP, lack a  -phosphate. This suggests a signiﬁcant contribu-
tion of the  -phosphate to ligand afﬁnity, and we note in the
structure of EcIspF that this group coordinates the active site
Zn2+. Despite their structural similarity, the binding afﬁnities
of 6 and 7 vary. The KD of 7 is comparable to that of CMP, but
6 binds about 20-fold weaker. Crystal structures of these ligands
bound to EcIspF were determined to investigate this observation.
Structural Characterization of Active Compounds. Co-
crystallization of EcIspF with compounds 6 and 7 gave crystals
that diffracted to 3.1 and 2.7 Å resolution, respectively (Table
2). However, the observed electron and difference density maps
suggested that hydrolysis has occurred at the ribose O2′ of 6,
producing a nonbridging phosphate at the 3′ position; therefore
6b (Table 1) was modeled and reﬁned satisfactorily. For
discussion purposes, the experimental ligand and protein active
site conformations are compared to CDP bound to EcIspF (PDB
1GX1) because this provided the template for docking. As
predicted, the compounds bind within the cytidine-binding
pocket of EcIspF. There are no major conformational changes
in the enzyme upon ligand binding as evidenced by the rmsd
differences (0.33, 0.29 Å) between CR atoms of the compound-
enzyme complexes 6b and 7 with 1GX1. The largest CR rmsd
differences occur in the ﬂexible loop (residues 62-71) that binds
ME2P. This loop is poorly ordered in the absence of a
ligand.
16,18
Compound 7comprises a cytosine, ribose, and phosphate similar
to CMP, but the phosphate bridges ring positions 3 and 4 (Table
1). Despite this difference, a structural comparison demonstrates
that 7 resembles the CMP fragment of CDP in its mode of binding
(Figure 5); all protein ligand interactions are maintained except
for those involving the  -phosphate of CDP, which has no
counterpart in 7. The cytosine moieties of both ligands bind,
forming a network of interactions to main chain atoms of Ala100,
Met104, Met105, and Leu106.
16 We note the possibility that a
bifurcated hydrogen bond is formed between the amide of Met103
and the pyrimidine N3 and O2 (Figure 5a). The ligand O2′ hydroxyl
forms hydrogen bonds to the carboxylate of Asp56 from one
subunit and water-mediated hydrogen bonds to the amide of Ala131
of a second subunit. Compound 7 interactions with EcIspF vary
from those of CDP in that the phosphate binds the side chain
hydroxyl of Thr133 through a water-mediated interaction rather
Figure 3. The pharmacophore hypothesis for inhibition of EcIspF. CDP is shown as a stick model together with the two metal ions (Mn2+ purple
sphere and Zn2+ gray sphere) and key residues in the active site of EcIspF. Atoms are colored C cyan, N blue, O red, P orange, S yellow. The large
red spheres mark hydrogen bond accepting groups of the ligand (A1 and A2) and the protein (A3-1 and A3-2), the blue spheres mark hydrogen
bond donor sites on the protein (D1, D2) and the ligand (D3), and the green sphere identiﬁes the hydrophobic component centered on the pyrimidine
ring.
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hydrogen bond linkage to the main chain carbonyl of Phe61. The
comparable binding afﬁnities of 7 and CMP are clearly due to their
chemical similarity and equivalent binding interactions with EcIspF.
Table 1. Potential IspF Ligands Identiﬁed by Virtual Screening
a
a Compound 6b was not identiﬁed by virtual screening but is a derivative of 6 likely generated following hydrolysis and was identiﬁed following the
crystal structure determination (see text). The ribose rings are numbered for 6, 6b, and 7. n.d. ) not determined.
2534 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 8 Ramsden et al.Compound 6 was selected to probe the speciﬁcity of the
binding pocket for different sugars as well as phosphate
placement. This compound contains a cytosine and a lyxose
with a phosphate bridging the 2 and 3 ribose positions (Table
1). Compound 6 was supplied as a mixture of anomers, but the
experimental density suggested that only the  -anomer of the
hydrolysis product 6b has bound (Figure 5b). Steric clash
between the R-anomer O5′ and side chains of Asp56 or Leu106
is the likely explanation for this observation. Despite this
unexpected modiﬁcation to the purchased compound, the
network of interactions between the cytosine moiety of com-
pound 6b and EcIspF is similar to that observed in the complex
with CDP. The binding interactions between the 6b sugar and
EcIspF resemble those observed between the ribose of CDP
and the enzyme. The O2′ and O4′ groups of both sugars form
hydrogen bonds with the side chains of Asp56 and Lys104,
respectively. The orientation and interactions of the phosphates
in C7 and 6b, however, vary from those observed in CDP
(Figure 5c,d). In the complex with 6b, the phosphate is directed
toward the Zn2+-binding site rather than forming a hydrogen
bond to the Thr132 side chain hydroxyl and an electrostatic
interaction with Mn2+ as observed in the CDP complex.
16 The
phosphate of 6b forms solvent-mediated hydrogen bonds with
the side chains of Asp46, Asp56, Thr132, and Thr133, the amide
of Gly58, and the carbonyl of Ala131. The effects on binding
afﬁnity of replacing ribose with lyxose and changing the
phosphorylation site are indeterminable because the relative
quantities of the anomers and the amount of hydrolyzed ligand,
present under assay conditions, are unknown.
Comparison of Predicted vs Experimental Binding
Modes. Comparison of models obtained by the computational
docking approach with structures determined by X-ray crystal-
lography give an indication of how reliable predictive modeling
can be for a speciﬁc system and may suggest where receptor/
target ﬂexibility or inﬂexibility can affect ligand binding. The
predicted and experimental poses of 7 have an rmsd difference
of 0.92 Å. The predicted interactions between the protein and
the cytosine moiety of the top ranked binding conformation of
7 are similar to those observed in the EcIspF-CDP complex
(Figure 5e), but the binding interactions of the ligand sugar and
phosphate with the protein differ due to side chain movements,
changes in the ﬂexible ME2P-binding loop, and slight differ-
ences in ligand conformation and placement (data not shown).
In the docked complex, a phosphate oxygen and O5′ are 2.9
Figure 4. Representative binding sensorgrams of CDP (a) and CMP (b) to covalently immobilized EcIspF. Reference-corrected SPR binding
curves for various concentrations of CDP and CMP monitored on a surface with ∼5000 RU of amine coupled EcIspF. The data were globally ﬁtted
using a kinetic model where a 1:1 complex is formed between EcIspF and CDP or CMP. The small graphs show the steady state (equilibrium) RU
after ﬁtting vs the concentrations of CDP or CMP. Running buffer was 50 mM sodium phosphate (pH 7), 2 mM MgCl2 and 0.005% surfactant P20.
In graph (a), curve a ) 25 µM CDP; b ) 50 µM CDP; c ) 100 µM CDP; d ) 200 µM CDP; e ) 400 µM CDP; f ) 800 µM CDP; g ) 1.6 mM
CDP. In graph (b), curve a ) 78.1 µM CMP; b ) 156.2 µM CMP; c ) 312.5 µM CMP; d ) 625 µM CMP; e ) 1.25 mM CMP; f ) 2.5 mM CMP;
g ) 5 mM CMP. Insets in (a) and (b): Nonlinear steady-state afﬁnity analysis for the corresponding interaction. The curve drawn is the best-ﬁt
curve to a single-site binding equation with the program GraphPad Prism. This provides an apparent Kd of 96.59 ( 6.45 µM for CDP and 903.63
( 10.77 µM for CMP.
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the crystal structure,  1 of Ile57 has changed so that CD1 is
shifted away from the ligand phosphate, the Asp63 side chain
has adjusted position, and the ligand is displaced from the
predicted binding site by approximately 0.6 Å to alleviate these
close contacts (data not shown). The crystal structure also
identiﬁes a shift in the side chain of Lys104 to form a hydrogen
bond to O4′ of the ligand (Figure 5b), an interaction not
predicted in the modeled complex.
We did not dock compound 6b in the active site of EcIspF.
In this case, the ligand has resulted from hydrolysis of compound
6, which had been docked previously. Comparisons indicated
that the position of the cytosine moieties agreed to the same
extent as seen for comparisons with 7 (data not shown).
Analysis of Cytosine Analogues. Our aim is to obtain ligand
scaffolds and through appropriate structural modiﬁcations to
improve binding afﬁnities. However, with limited structural
diversity of potential EcIspF ligands identiﬁed through virtual
screening, in essence a single chemotype, it was decided to
rationally select compounds to investigate the binding properties
of part of the active site. Fluorescent substrate analogues have
been used to examine the ﬂexible loop that binds the substrate
fragment ME2P and how this loop adjusts to a variety of
aromatic scaffolds.
32 Here, we restricted our investigation to
probing the cytidine- and Zn2+-binding sites using cytosine
analogues and common metal ion binding moieties, respectively.
Both sets of compounds represent potential building blocks with
beneﬁcial pharmacokinetic properties and scope for optimization.
Three compounds were selected to investigate how small
modiﬁcations to the ribose and cytosine moieties affect binding.
Cidofovir (CDV), cytosine arabinoside monophosphate (AraC-
MP), and 5-ﬂuorocytidine (FLUC) were chosen to probe the
effects, respectively, of removing the sugar, altering chirality
at C2′ , and of whether a particular covalent modiﬁcation on
the cytosine ring was tolerated (Table 3). AraCMP and CDV
are drugs used in cancer and viral therapies.
33,34 The complex
structures of AraCMP, FLUC, and CDV with EcIspF were
determined to 2.1, 2.5, and 2.8 Å resolution (Table 2),
respectively, and ligand binding afﬁnities determined using SPR
(Table 3). Most of the protein residues are well deﬁned in the
electron density maps for all structures except for residues
62-71, which form the ﬂexible ME2P binding site and are
poorly ordered. There are no major conformational changes upon
ligand binding, as evidenced by the rmsd differences of 0.27,
0.36, and 0.25 Å for the overlay of CR atoms of the
compound-enzyme complexes FLUC, AraCMP, and CDV,
respectively, with the CDP complex, PDB code 1GX1. The
crystal structures of the complexes conﬁrm that the ligands are
ﬁrmly anchored in the cytidine-binding pocket (Figure 6). The
cytosine moiety of each ligand forms the same network of
interactions to the main chain of Ala100, Lys104, Met105, and
Leu106, as observed in the complex with CDP.
16 AraCMP,
FLUC, and CDV bind in a similar manner to CMP and CDP
(Figure 6).
The asymmetric unit of the EcIspF-AraCMP complex crystal
structure contains six subunits. Five of the active sites are
occupied by ordered AraCMP molecules, and the protein-ligand
interactions (Figure 6a) are identical in each case. To prevent
steric clash of the O2′ hydroxyl with Asp56 and Ala131, the
cytosine moiety of AraCMP moves slightly away from the
backbone of EcIspF compared to the CMP fragment of CDP
(data not shown). This allows the formation of a hydrogen bond
between O2′ and the carbonyl of Ala131. O2′ also participates
in a water-mediated interaction to the amide of Ala131. The
O3′ group forms a water-mediated hydrogen bond with the
amide of Gly58. This is in contrast to the interactions made by
the O2′ and O3′ groups of CDP, which both form direct
hydrogen bonds to the side chain of Asp56 and, for the latter
only, to the amide of Gly58.
16 Like the CMP fragment of CDP,
the phosphate group of AraCMP interacts with side chain and
main chain atoms of Thr132 and Thr133. Overall, AraCMP
forms between 8 and 9 direct hydrogen bonds compared to
Table 2. Data Processing and Reﬁnement Statistics of EcIspF Ligand Complexes
ligand code 6b 7 AraCMP FLUC CDV
Crystal morphology cube cube plate plate cube
X-ray source ID29 ID29 ID29 RU-200 RU-200
wavelength (Å) 0.9756 0.9756 0.9756 1.5418 1.5418
space group I213 I213 P21 C2 I213
unit cell:
a (Å) 144 144.5 88.8 104.68 145.68
b (Å) 54.2 54.83
c (Å) 118.4 88.51
  (deg) 95 99.66
resolution range (Å) 29.4-3.1 29.5-2.7 20-2.1 50-2.5 29.7-2.8
no. of measurements
a 111733 202013 329171 382131 186443
no. of unique reﬂections 9178 13944 71490 15989 12818
redundancy 12.5 14.5 4.6 27.04 14.5
overall completeness (outer shell, %)
b 99.9 (96.6) 99.9 (97.8) 94.3 (71.8) 91.4 (80.4) 99.9 (97.6)
mean 〈 I/σ(I)〉 23.6 (7.3) 24.2 (8.9) 18.4 (1.6) 8.1 (2.2) 30.4 (5.0)
Rsym (%)
b 10 (32.6) 9.9 (27.4) 8.9 (47.7) 8.5 (20.3) 8.7 (47.6)
solvent content (%) 80 80 50 45 80
monomers per a.u.
c 11631
Rfree/Rwork (%) 21.9/18.7 21.8/18.4 23.7/21.8 29.1/20.8 19.9/16.0
protein residues 157 162 942 471 157
water molecules 37 97 284 113 42
average B values (Å2)
protein 60.7 33.5 33.3 49.6 55.5
main chain 60.3 33.0 32.0 49.3 54.6
side chain 61.2 34.0 34.8 49.9 56.4
solvent 54.8 34.4 38.0 45.1 59.9
ligand 58.4 42.2 45.7 58.5 62.6
bond length rmsd (Å) 0.012 0.013 0.009 0.012 0.023
bond angle rmsd (deg) 2.22 1.55 1.24 1.41 2.02
a As reported in SCALA, including partials.
b Values in parentheses refer to the highest resolution shell of about 0.1 Å width.
c a.u. ) asymmetric unit.
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( 5.8 mM, which is 20-fold weaker than CMP (0.903 ( 0.107
mM). Although the active site can accommodate a change in
chirality at C2′ , this is accompanied by a large, unfavorable
effect on binding afﬁnity.
The same network of protein-pyrimidine interactions is
observed in the FLUC complex (Figure 6b), although the
cytosine pocket of the enzyme has expanded slightly to
accommodate the additional substituent on the pyrimidine. The
distance between the CR atoms of Thr133 and Leu106 of the
same subunit deﬁnes one dimension of the enzyme active site
and is slightly longer in the FLUC complex (12.5 Å) compared
to the CDP complex (11.9 Å). In the FLUC complex, the
cytosine moiety shifts closer to Met105 and Leu106 compared
to the CDP complex, allowing the formation of a hydrogen bond
between the ﬂuorine and main chain amide of Thr133. In the
CDP complex, the R-phosphate accepts a hydrogen bond from
this amide group. The pyrimidine shift in the FLUC complex
Figure 5. EcIspF-ligand complexes. The active site of EcIspF in complex with (a) 7, (b) 6b, (c) superposition of CDP on 7, (d) superposition of
CDP on 6b, and (e) superposition of the top docked 7 pose in EcIspF-CDP and EcIspF-7. In (a) and (b), the Fo - Fc omit map contoured at 3σ
and colored green is shown and black dashed lines indicate putative hydrogen bonds. Zn2+ and water molecules are represented as gray and blue
spheres, respectively, and the gray dashed lines represent metal ion ligand coordination. Protein residues labeled with a prime indicate that they
belong to a partner subunit. Atoms are colored as followed: C atoms of the protein are cyan, N blue, O red, S yellow, P orange, ligand C atoms
are black, and CDP and docked 7 C atoms are gray. In (e), C atoms of the protein in the EcIspF-CDP complex are gray.
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causes the side chain of Leu106 to shift away from the ligand
to prevent steric clash. Although FLUC has no phosphate group,
the binding afﬁnity (2.02 ( 0.42 mM) is similar to that of CMP
(0.903 ( 0.107 mM), implying that the ﬂuorine atom compen-
sates for the loss of phosphate-derived electrostatic interactions.
Binding of FLUC by EcIspF suggests that additional pyrimidine
substituents could be accommodated by the enzyme active site
and further systematic investigation to determine the limits on
the number, size, and chemical properties of additional substit-
uents that can be accommodated are warranted.
The cytosine moiety of CDV forms the same interactions with
the protein as previously described for CDP,
16 which are the
only direct interactions with the protein; all other hydrogen
bonds are solvent-mediated (Figure 6c). The interactions
between the noncytosine fragment of CDV and protein resemble
those solvent-mediated interactions formed between EcIspF with
the ribose and R-phosphate moieties of CDP. Solvent-mediated
interactions between CDV and EcIspF include ligand phosphate
associations with the side chains of Asp56, Asp63, Thr132, and
the amides of Ala131 and Thr133. The lack of direct hydrogen
bonding interactions between the ligand and enzyme probably
contributes to the weak binding afﬁnity (∼40 mM) of CDV for
EcIspF.
Analysis of Zn2+-Binding Moieties. Hydroxamates and
sulfonamides are among the most common Zn2+-binding ligands.
35
Six compounds (Table 4), three hydroxamates (11-13), and three
sulfonamides (14-16), were selected for this study based on
commercial availability and mass to ensure that the putative ligands
were small enough to bind within the EcIspF active site. Cocrys-
tallization of all six compounds with EcIspf was attempted, but,
for reasons we cannot explain, no crystals were obtained. The
sulfonamide compounds were only soluble in DMSO, thus hinder-
ing the SPR binding assay. The hydroxamates were soluble in assay
buffer but no measurable data were obtained for 11 and 12,
probably due to their small mass. The change in refractive index
for binding of a ligand smaller than 180 Da is likely too small to
be detected on a BiaCore 3000 instrument (John Butler, personal
communication). The SPR binding assay was able to quantify the
binding afﬁnity of 13, yielding a KD of 1.92 (0.18 µM. Compound
Table 3. Cytosine Derivatives
a
a Ligand codes, names, structures, molecular weight, and binding afﬁnities are given.
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and we attribute this to Zn2+-hydroxamate coordination. Similar
observations apply to other Zn2+-dependent enzymes, including
E. coli LpxC, an enzyme in the lipid A biosynthesis pathway.
Kinetic studies of LpxC revealed that replacing a carboxylate group
on 4,5 dihydro-2-phenyloxazole-4-carboxylic acid with hydrox-
amate lowered the IC50 from >400 to 3 µM.
36 Our observations
suggest that the addition of a Zn2+-binding moiety may prove
valuable in assisting the design of potent and selective inhibitors
of EcIspF. In this, one possible strategy could be to develop
molecules tethered by a Zn2+-binding moiety to the catalytic center,
which then extend to the cytosine-binding pocket where very clear
and conserved molecular features could assist the incorporation of
speciﬁcity (Figure 1B). Because the Zn2+ location is within
proximity of the ME2P binding site, then there is also the potential
to extend from a metal-binding group using molecular fragments
that mimic the methylerythritol component of substrate, a moiety
that also interacts with a highly conserved part of the enzyme.
Ligand Efﬁciency to Compare Compounds. Previously
reported ﬂuorescent substrate analogues
32 have greater afﬁnity for
EcIspF and a measurable gain in binding free enthalpy compared
to the compounds in this study. Although potency is an important
criterion for assessing lead compounds it can be misleading.
37 A
useful parameter for assessing the potential of a weak lead for
inhibitor design is to calculate the binding energy per non-hydrogen
atom for each ligand, or ‘ligand efﬁciency’ (∆g).
38 This parameter
was calculated using equation 1.1 for the compounds in this study
(except 6), and the substrate fragments CDP and CMP (Table 5).
where ∆G )- RT ln Kd and N is the number of non-hydrogen
atoms.
Interestingly, FLUC (-0.81 kJ·mol-1/non-H atom) has a
ligand efﬁciency comparable to CDP (-0.87 kJ·mol-1/non-H
atom) and CMP (-0.79 kJ·mol-1/non-H atom). Although the
ﬂuorescent substrate analogues have greater potency, they have
lower ligand efﬁciencies (-0.64 to -0.70 kJ·mol-1/non-H
atom) compared to CMP. The aromatic moieties added to the
substrate-like entities beneﬁt binding afﬁnity,
32 but they do not
improve ligand efﬁciency. Compound 13 has the best ligand
efﬁciency with a ∆g value of -2.04 kJ·mol-1/non-H atom. This
is signiﬁcantly improved over CDP yet much weaker in
comparison to the average value associated with a drug in
clinical use (-6.3 kJ·mol-1/non-H atom).
38
Conclusions
In this study, virtual screening for potential ligands of EcIspF
was performed exploiting a hierarchical ﬁltering methodology
followed by molecular docking with the program FlexX.
Application of an SPR assay and crystallographic studies has
served to characterize two weak binding ligands. These initial
results prompted further elucidation of the binding properties
of EcIspF by analyzing cytosine derivatives again using
crystallography and SPR. The cytosine-binding site of EcIspF
can tolerate small structural modiﬁcations of the pyrimidine,
as evidenced by binding of FLUC. Modiﬁcations to the ribose,
particularly at C2′ , are detrimental to binding afﬁnity but do
not preclude ligand binding as seen in the complexes with
AraCMP and CDV. The incorporation of solvent mediated
hydrogen-bonding interactions, linking functional groups on the
ligands to the enzyme, appears to compensate for alterations in
the structure of the ligands compared to substrate.
Generally, when a nucleoside or nucleotide represents a
fragment of substrate, this fragment alone does not contribute
Figure 6. Cytosine-based compounds binding to EcIspF. The active site of EcIspF in complex with (a) AraCMP, (b) FLUC, and (c) CDV. In each
case, the Fo - Fc omit map is shown as green chicken wire and contoured at 3σ. The color scheme is similar to Figure 5.
∆g ) ∆G/Nnon-hydrogen atoms (1.1)
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enzyme LpxC, which has a Km >20 mM for UDP-GlcNAc and
2.1 µM for UDP-3-acyl-GlcNAc, the natural substrate.
39,40 In
such cases, potent inhibition might best be sought by targeting
part of the active site that does not belong to the nucleotide
binding pocket. The tight binding of the hydroxamate 13,
postulated to bind the active site Zn2+, provides support for
incorporation of metal binding moieties to design potent
inhibitors. While hydroxamates can lack speciﬁcity,
35 incorpora-
tion of such a group onto cytosine analogues offers potential
as a strategy to improve selectivity and potency for novel
inhibitors of EcIspF.
Experimental Section
Hierarchical Filtering. We used the same virtual screening
database that was compiled for a previous study.
29 In short, this
database contained the three-dimensional structures of small
molecules stored in the Available Chemicals Directory and of
screening compounds supplied by ﬁve companies, namely Ambint-
er, Asinex, ChemStar, InterBioScreen, and Tripos. In total, 826952
commercially available compounds were stored in this database.
Filtering for compounds that possessed at least two hydrogen bond
donors, two hydrogen bond acceptors, and one hydrophobic region
(a ﬁve- or six-membered ring) was performed using SELECTOR.
41
The pharmacophore search was performed using UNITY
42 with
the Lipinski’s “rule of ﬁve” check activated.
43
Docking. Ligands were docked into the binding site of EcIspF
(PDB 1GX1) using FlexX v1.3.
26 The DrugScore
44 scoring function
was applied during the placement and construction phase and for
ranking.
Protein Preparation. All chemicals purchased were of the highest
purity available. IspF was expressed in E. coli strain BL21 (DE3) and
puriﬁed following published methods.
16 The protein concentration was
determined spectrophotometrically using a theoretical extinction coef-
ﬁcient of 8370 M-1·cm-1 at 280 nm and purity assessed as being
Table 4. Table of Selected Hydroxamate and Sulfonamide Compounds
a
a Ligand codes, names, structures, molecular weight (MW) and binding afﬁnities are shown. n.d. ) not determined.
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ionization time-of-ﬂight mass spectrometry.
SPR Biosensor Studies. SPR experiments were performed on
a Biacore 3000 (Biacore, Uppsala, Sweden) instrument with CM5
research grade chips (Biacore, Uppsala, Sweden). Sensorgrams were
recorded at a frequency of 2.5 Hz. EcIspF was immobilized using
amine-coupling chemistry. Brieﬂy, the sensor chip surface was
activated with three 6 min injections at 5 µL min-1 of a mixture of
N-hydroxysuccinimide at 115 mg mL-1 and 1-ethyl-3-(3-dimethy-
laminopropyl) carbodiimide hydrochloride at 750 mg mL-1. EcIspF
was diluted with 10 mM acetate buffer pH 5.5 to a ﬁnal
concentration of approximately 100 µgm L -1 and applied to the
chip so that readings between 4500 and 5500 response units were
obtained. After immobilization, a 6 min injection at 5 µL min-1 of
1 M ethanolamine was used to quench excess active succinamide
ester groups. SPR binding experiments with EcIspF were performed
at 10 °C in 50 mM sodium phosphate pH 7 and 2 mM MgCl at a
ﬂow rate of 30 µL min-1. The sensor surface was regenerated
between experiments by applying the running buffer for 20 min to
dissociate any ligand complex. This was followed by a further 20
min stabilization period. Immobilized EcIspF is not amenable to
more stringent and rapid regeneration conditions (data not shown).
The 40 min total regeneration time between experiments helped to
eliminate any carry-over of EcIspF bound to ligand. A concentration
series, ranging from 0.1 µM to 10 mM, of ligand was typically run
in these experiments. Each injection at a given concentration was
repeated three times. Blank injections were included for each
measurement series and subtracted from the data. The equilibrium
(steady state) binding curves were analyzed by nonlinear regression
and ﬁt to a one-to-one Langmuir binding model. All ligands
assessed by SPR were greater than 95% purity as established by
high-performance liquid chromatography or combustion analysis.
Crystallization and Structure Determination. Crystals were
obtained by vapor diffusion at 20 °C with 3 µL hanging drops over
a 250 µL reservoir solution. Ligand cocrystallization conditions
varied depending on the ligand and protein concentrations (Table
6). After 1-10 days, crystals displaying one of two morphologies,
cubic blocks or plates, grew to an average size of 0.4 mm and 0.4
× 0.4 × 0.05 mm3, respectively. Crystals were harvested from the
drops and soaked in a mixture of cryoprotectant (Table 6) and
mother liquor for approximately 30 s and then cooled in a nitrogen
gas stream at -170 °C for data collection. Data sets for EcIspF in
complex with 6b, 7, and AraCMP were measured on beamline ID29
with a Q210 2D detector (Area Detector Systems Corp.) at the
European Synchrotron Radiation Facility, and EcIspF in complex
with CDV and FLUC were measured in-house using an RU-200
rotating-anode generator (Cu KR, λ ) 1.5418 Å) with an R-Axis
IV image plate detector (Rigaku). Data were processed with
MOSFLM
45 and scaled using the CCP4 program suite.
46 The
complexes of EcIspF with 7, AraCMP, and FLUC were solved by
molecular replacement with AMoRe
47 using a monomer from the
published EcIspF structure (PDB 1GX1). Complex structures of
EcIspf with 6 and CDV were derived from the 7 complex structure
by rigid body reﬁnement. The models were reﬁned with REFMAC
48
using established protocols,
49 together with several rounds of
manual alteration in COOT
50 or O.
51 Superpositions were calculated
using LSQMAN
52 and ﬁgures produced using PyMOL.
53
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